IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the…

IMAC Holdings, Inc.

BRENTWOOD, Tenn., Sept. 09, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (IMAC or the Company), today announces it has completed the third cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinsons disease.

The third cohort consists of five patients with bradykinesia due to Parkinsons disease receiving an intravenous infusion of a high concentration stem cell treatment. The third and final cohort of the Phase 1 clinical trial was completed on Tuesday, September 6, 2022.

About IMACs Phase 1 Clinical Trial

The Phase 1 clinical trial, consisting of a 15-patient dose escalation safety and tolerability study, is being conducted at three of IMACs clinical centers in Chesterfield, Missouri, Paducah, Kentucky, and Brentwood, Tennessee. The trial is divided into three groups: 1) five patients with bradykinesia due to Parkinsons disease received a low concentration dose, intravenous infusion of stem cells, 2) five received a medium concentration intravenous dose, 3) and five received a high concentration intravenous dose. All groups will be subsequently tracked for 12 months. IMACs medical doctors and physical therapists at the clinical sites have been trained to administer the treatment and manage the therapy. Ricardo Knight, M.D., M.B.A., who is medical director of the IMAC Regeneration Center of Chicago, is the trials principal investigator.

The Institute of Regenerative and Cellular Medicine serves as the trials independent investigational review board, while Regenerative Outcomes provides management of the study. Further details of the trial can be found at clinicaltrials.gov.

About Bradykinesia Due to Parkinsons Disease

In addition to unusually slow movements and reflexes, bradykinesia may lead to limited ability to lift arms and legs, reduced facial expressions, rigid muscle tone, a shuffling walk, and difficulty with repetitive motion tasks, self-care, and daily activities. Parkinsons disease is the typical culprit of bradykinesia, and as it progresses through its stages, a persons ability to move and respond declines.

Story continues

According to Zion Market Research, the global Parkinsons disease therapeutics market was $2.61 billion in 2018 and is expected to grow to $5.28 billion by 2025. The Parkinsons Disease Foundation estimates that nearly 10 million people are suffering from Parkinsons disease, and almost 60,000 new cases are reported annually in the U.S.

About IMAC Holdings, Inc.

IMAC Holdingsowns and manages health and wellness centers that deliver sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases.IMACis comprised of three business segments: outpatient medical centers, The Back Space, and a clinical research division. With treatments to address both young and aging populations,IMAC Holdingsowns or manages outpatient medical clinics that deliver regenerative rehabilitation services as a minimally invasive approach to acute and chronic musculoskeletal and neurological health problems. IMACs The Back Company retail spinal health and wellness treatment centers deliver chiropractic care within Walmart locations. IMACs research division is currently conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinsons disease. For more information visitwww.imacholdings.com.

# # #

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as anticipate, expect, believe, may, will, should or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact:

Laura Fristoe

lfristoe@imacrc.com

See the rest here:
IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the...

Top 3 grants in regenerative medicine: July 2022 – RegMedNet

This months top grants in regenerative medicine, sourced from Dimensions, includes projects on: a novel platform to enhance single cell interrogation of nervous system development, human endothelial cell regulation of ossification and the development of a dynamic double network hydrogel for generating pancreatic organoids from induced pluripotent stem cells.

This project aims to investigate a strategy, which utilizes novel spatial transcriptomics approaches, integrated multiplexed RNA/protein detection and visualization and computational algorithms to identify and map molecular markers of the preganglionic neurons in the ventral spinal cord and progenitor cell populations of the sympathetic ganglia. If successful, the approach could provide a foundation for basic research of peripheral nervous system birth defects and repair using stem cell-based therapies, as well as future studies of neuroblastoma initiation.

Funding amount:US$206,000

Funding period: 8 August 2022 31 July 2024

Funder:Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Research organization:Stowers Institute for Medical Research (MO, USA)

Read more

Over one million patients undergo bone repair procedures in the USA annually, with autologous bone grafting remaining the preferred treatment for bone defects. The development of therapies that exploit the osteogenic potential of bone marrow-derived mesenchymal stem cells (bm-MSCs) has been limited due to limited understanding of the regulatory mechanisms of in vivo bm-MSC osteogenesis. Previous research from the group showed that the osteogenic potential of bm-MSCs is dependent on sustained proximity to endothelial cells. The goal of the present study is to elucidate the cellular and molecular mechanisms by which endothelial cells regulate the osteogenic differentiation of bm-MSCs and develop a foundation of knowledge upon which to build therapeutic strategies for bone regeneration utilizing autologous bm-MSCs.

Funding amount:US$442,000

Funding period: 10 August 2022 31 May 2027

Funder:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Research organization:Boston Childrens Hospital (MA, USA)

Read more

Human induced pluripotent stem cells provide a valuable source of cells for basic research and translational applications. While there have been advances in lineage-specific differentiation of human induced pluripotent stem cells, there remains limited understanding on the impact of matrix stiffness, viscoelasticity and integrin ligand presentation on the multi-stage development of exocrine pancreatic organoids. This research aims to define the influence of matrix properties on the generation of exocrine pancreatic organoids by developing a viscoelastic dynamic double network hydrogel platform with controllable matrix mechanical properties and biochemical motifs. This will advance the application of chemically defined matrices as xeno-free artificial stem cell niches for organoid growth and tissue regeneration applications.

Funding amount:US$468,000

Funding period: 1 August 2022 31 July 2026

Funder:National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Research organization: Indiana University Purdue University Indianapolis (IA, USA)

Read more

Brought to you with support from:

View post:
Top 3 grants in regenerative medicine: July 2022 - RegMedNet

New Method Promises to Yield More Therapeutic T Cells – Medscape

Producing the T lymphocytes that are increasingly being used to fight cancer and other diseasesmay soon be faster and more efficient, thanks to research being conducted at the University of British Columbia, in Vancouver, Canada.

Investigators found that adding the human proteins DLL4 and VCAM1 rather than using traditional animal products during a key cellular transition phase enhanced downstream output of progenitor T cells from pluripotent stem cells (PSCs) about 80-fold. The recombinant human proteins targeted the endothelial-to-hematopoietic (EHT) phase of development. If scaled up, the new process could substantially increase the availability and affordability of personalized T-cell immunotherapy.

Dr Yale Michaels

"Our goal is to be able to take cells from human donors, genetically modify and produce them in high numbers, and then store them in the freezer for off-the-shelf medicine," study author Yale S. Michaels, DPhil, postdoctoral fellow in biomedical engineering, told Medscape Medical News. "We think our technique will be ready for trials in humans within a couple of years."

The findings were published online August 24 in Science Advances.

Chimeric antigen receptor and engineered T-cell receptor T cells have demonstrated high clinical efficacy against some cancers. They also show promise for treating infection and immunologic disorders and for preventing transplant rejection, the authors write.

But sourcing these therapeutic cells from individual donors is costly and laborious, they add. Inter-donor variability and intra-donor heterogeneity make the production and quality control of personalized T-cell therapies challenging. The efficacy rate of this type of therapy is close to 50% for some cancers, but a new batch must be created for each treatment, and the cost is about half a million dollars each round, according to the researchers. Using PSCs to create immune cells in the laboratory could facilitate the derivation of hundreds of doses from a single cell.

Differentiating PSCs specifically into hematopoietic progenitors with T-cell potential remains difficult. "How to make the right type of cells from PSCs in the lab has been really challenging," said Michaels. "Previously, shepherd, or guide, cells from mouse cell lines or cow serum were used, but these shepherd cells produce so many different factors and components that it was hard to understand the minimum signals necessary to do the required job."

Michaels and his team believed that a pathway called notch signaling, which DLL4 and VCAM1 help to activate, would be important in the development of differentiated blood cells. As it turns out, VCAM1 cooperates with DLL4 to enhance the magnitude of notch signaling during the EHT culture phase. "We set out to understand the minimal signaling requirements for generating hematopoietic progenitors with T-cell potential from human PSCs," said Michaels.

The investigators coated lab Petri dishes with the DLL4 and VCAM1 proteins and added stem cells and growth media to foster the growth of blood cells with T-cell potential. "Production became faster and more efficient. As an added advantage, without the use of animal products, manufacturing can be done in a quality-controlled way that is easy to replicate and will make it suitable for clinical use," said Michaels.

Unexpectedly, the investigators also found that VCAM1 promoted inflammatory-responsive gene expression in hematopoietic stem cells. Studies in zebrafish and mice have shown that inflammatory signals are important for the emergence of these cells, both upstream and downstream of the notch pathway, they note.

Offering an oncologist's perspective, Cassian Yee, MD, a professor of melanoma medical oncology and immunology at the University of Texas MD Anderson Cancer Center in Houston, agreed that ultimately, the goal is to prescribe off-the-shelf treatment with T cells designed for a given cancer type and stage. "The method described by Michaels et al is a significant step in that direction," he told Medscape. The technique "utilizes well-defined reagents that could likely be rendered clinical-grade compatible for ex vivo manufacturing and is able to produce a diverse T-cell repertoire." Yee was not involved in the current study.

Dr Cassian Yee

But many steps remain before that goal is reached, Yee cautioned. Among them are identifying and engineering T cells with the desired specificity, enriching and expanding them efficiently from a PSC-derived product with the desired intrinsic properties, and achieving scalability. "But I believe that ultimately, these issues are all addressable and this technology opens the door a little wider to that possibility," said Yee.

The research was funded by Notch Therapeutics, the Stem Cell Network Fueling Biotechnology Partnerships, the Canadian Institute for Health Research Foundation, and the Wellcome Leap Human Organs, Physiology, and Engineering program. Michaels is an inventor of patents relating to T-cell differentiation and consults for regenerative medicine companies, including Notch Therapeutics. Yee sits on the advisory boards of several cell therapy companies, but none are engaged in research relevant to his comments.

Sci Adv. Published online August 24. Full text

Diana Swift is a medical journalist based in Toronto. She can be reached at dianaswift@rogers.com.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Visit link:
New Method Promises to Yield More Therapeutic T Cells - Medscape

Stem Cell Therapy Approach On War Injury Patients – NewsPatrolling

Peshmerga Army Invites Dr Pradeep Mahajan To Addressed a treatment using Stem Cell Therapy on injured wounds

Mumbai: Stem cell therapy possesses both diagnostic and therapeutic potential. The use of stem cells for pain management can help with fast, safe, effective, and lasting results in terms of injuries. Dr. Pradeep Mahajan, Regenerative Medicine Researcher, StemRx Bioscience Solutions Pvt. Ltd conducted a session on the benefits of stem cell therapy to help the Peshmerga Army bounce back from serious injuries. Indian High Commissioner attended the meeting Consul general of India Subhash C. Kain attended a meeting with the commander in chief Houshmmad of Peshmerga & Major Dr. Dana A. Ali

Stem cells therapy can be used for the treatment of injuries where surgery does not heal wounds of skin muscles, tendons, bones, the sensory part, solid organs, nervous system and other skeleton muscle and pulmonary tissues , also it will look into radiation syndromes to treat using stem cells.

Stem cell therapy has been a boon for a large number of patients and is becoming increasingly popular. It is used to treat complex diseases without any complications. Stem cell therapy will not only yield positive results in common people but army men too. The Peshmerga forces have sacrificed a lot during the war against the ISIS terrorist group in the last decade to protect their country and the entire world from terrorist threats. Unfortunately, as a result of the war, besides thousands of Peshmerga have been martyred, more than 10,000 peshmergas have been injured critically. Some of them are fully healed, while others still need to be treated. To promptly tackle the need of the soldiers, Dr Pradeep Mahajan has been invited by the Ministry of Peshmerga, Kurdistan.

Dr Pradeep Mahajan, Regenerative Medicine Researcher, StemRx Bioscience Solutions Pvt. Ltd said, It was an honor to deliver a lecture on stem cell therapy for Peshmerga forces in Kurdistan. If there is war then there are going to be injuries. I briefed them about how revolutionary stem cell therapy can be a game changer for them when it comes to untreatable diseases. I respect the army men for their courage, spirit, and love towards the country. It was a proud moment for me to deliver a lecture for them. I hope to get more such opportunities in the near future and help the army men to overcome injuries and improve their quality of life.

It is a proud moment for the Indian Community to extend the high technology to improve the recovery of a war injury.

See original here:
Stem Cell Therapy Approach On War Injury Patients - NewsPatrolling

Cell Therapy And Acellular Therapy Market See Huge Growth for New Normal | Aegle Therapeutics Corp, ArunA Biomedical – Fighting Hawks Magazine -…

California (United States) Cell Therapy And Acellular Therapy Market research is an intelligence report with meticulous efforts to study the right and valuable information. The data that has been looked upon is done considering the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well-explained SWOT analysis, revenue share, and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs, and Tables) of this report @:

Some of the Top companies Influencing this Market include:

Aegle Therapeutics Corp, ArunA Biomedical, Capricor Therapeutics, Inc., Codiak BioSciences, Inc., Direct Biologics, LLC, EV Therapeutics, Inc., Evox Therapeutics Ltd, Exogenus Therapeutics, Invitrx Therapeutics, Inc., Organicell Regenerative Medicine, Inc., Rion LLC, Stem Cell Medicine Ltd..

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists the restraints that are posing a threat to the global

Global Cell Therapy And Acellular Therapy Market Segmentation:

Market Segmentation: By Type

Cell Therapy Acellular Therapy

Market Segmentation: By Application

Cardiology Hepatology Neurology Gastroenterology Oncology

The report provides insights on the following pointers:

Market Penetration: Comprehensive data on the product portfolios of the top players in the Cell Therapy And Acellular Therapy market.

Product Development/Innovation: Detailed information about upcoming technologies, R&D activities, and market product debuts.

Competitive Assessment: An in-depth analysis of the markets top companies market strategies, as well as their geographic and business segments.

Market Development: Information on developing markets in their entirety. This study examines the market in several geographies for various segments.

Market Diversification: Extensive data on new goods, untapped geographies, recent advancements, and investment opportunities in the Cell Therapy And Acellular Therapy market.

Get Up to 30% Discount on the first purchase of this report @:

Global Cell Therapy And Acellular Therapy market Report Scope:

The cost analysis of the Global Cell Therapy And Acellular Therapy Market has been performed while considering manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy considered.

Key questions answered in this report:

Table of Contents

Global Cell Therapy And Acellular Therapy Market Research Report 2022 2029

Chapter 1 Cell Therapy And Acellular Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy, and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Cell Therapy And Acellular Therapy Market Forecast

Buy Exclusive Report:

If you have any special requirements, please let us know, and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

+1 775 237 4157

Cell Therapy And Acellular Therapy, Cell Therapy And Acellular Therapy market, Cell Therapy And Acellular Therapy market research, Cell Therapy And Acellular Therapy market report, Cell Therapy And Acellular Therapy Market comprehensive report, Cell Therapy And Acellular Therapy market forecast, Cell Therapy And Acellular Therapy market growth, Cell Therapy And Acellular Therapy Market in Asia, Cell Therapy And Acellular Therapy Market in Australia, Cell Therapy And Acellular Therapy Market in Europe, Cell Therapy And Acellular Therapy Market in France, Cell Therapy And Acellular Therapy Market in Germany, Cell Therapy And Acellular Therapy Market comprehensive analysis, COVID 19 impact on Cell Therapy And Acellular Therapy market, Aegle Therapeutics Corp, ArunA Biomedical, Capricor Therapeutics, Inc., Codiak BioSciences, Inc., Direct Biologics, LLC, EV Therapeutics, Inc., Evox Therapeutics Ltd, Exogenus Therapeutics, Invitrx Therapeutics, Inc., Organicell Regenerative Medicine, Inc., Rion LLC, Stem Cell Medicine Ltd.

Read more:
Cell Therapy And Acellular Therapy Market See Huge Growth for New Normal | Aegle Therapeutics Corp, ArunA Biomedical - Fighting Hawks Magazine -...

Global Cell Culture Market to Grow by 11.99% Annually Through 2029 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Cell Culture Market Analysis by Product, by Application, by End User, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

The global cell culture market size is valued to be USD 19.78 billion in 2021 and is anticipated to witness a CAGR of 11.99% during the forecast period. Growth in awareness regarding the advantages of cell culture-based vaccines is a key driver for the growth of the global cell culture market. Additionally, increase in demand for monoclonal antibodies and subsidy offered to cell-based research in the cell culture market is some of the other drivers propelling the market growth. Nevertheless, high cost of cell culture treatment and shortage of structure for cell-based research in emerging economies are expected to restrain the global market growth.

By Product

Based on product segment, the market is sub-segmented into consumables and equipment. In 2021, the consumables segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the recurrent purchase of consumables along with increasing subsidy for cell-based research. worldwide. Equipment segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to the increasing risk of pandemic and communicable diseases.

By Application

Based on application, the market is segmented into biopharmaceutical production, diagnostics, drug screening and development, stem cell research, tissue engineering & regenerative medicine, and other applications. In 2021, the biopharmaceutical production segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to growing governing sanctions for the manufacture of cell culture-based vaccines along with an increasing demand for monoclonal antibodies (mAbs) worldwide. Stem cell research segment is expected to grow at a profitable CAGR during the forecast period. This is attributed to the growth in advancements of proteomic gene expression and consequent growth of new vaccine and biopharmaceuticals globally.

By End User

Based on end user, the market is categorized into cell banks, pharmaceutical & biotechnology companies, academic & research institutes, and hospitals and diagnostic laboratories. In 2021, the pharmaceutical & biotechnology companies segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is due to the growth in application of single-use technologies along with the increase in number of regulatory sanctions for manufacturing of cell culture-based vaccines worldwide. The cell banks segment is anticipated to grow at a profitable CAGR during the forecast period, due to the rise in incidence of chronic diseases that have resulted in increase in cell biology & cytological studies.

Consumables

Bioreactor Accessories

Equipment

Supporting Equipment

Other Supporting Equipment

Single-Use Bioreactors

Storage Equipment

Cell Culture Market, By Application (Revenue, USD Billion, 2021-2029)

Biopharmaceutical Production

Cell Culture Market, By End User (Revenue, USD Billion, 2021-2029)

Cell Culture Market, By Region (Revenue, USD Billion, 2021-2029)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Key Topics Covered:

1. Research Methodology

2. Introduction: Cell Culture

3. Executive Summary

4. Market Dynamics

5. Market Environment Analysis

6. COVID-19 Impact Analysis: Cell Culture Market

7. Market Analysis by Product

8. Market Analysis by Application

9. Market Analysis by End User

10. Regional Market Analysis

11. North America Cell Culture Market

12. Europe Cell Culture Market

13. Asia Pacific Cell Culture Market

14. Latin America Cell Culture Market

15. MEA Cell Culture Market

16. Competitor Analysis

17. Company Profiles

18. Conclusion & Recommendations

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/g47hlz

Originally posted here:
Global Cell Culture Market to Grow by 11.99% Annually Through 2029 - ResearchAndMarkets.com - Business Wire

Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth – Yahoo…

Company Logo

Dublin, Sept. 06, 2022 (GLOBE NEWSWIRE) -- The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2022" report has been added to ResearchAndMarkets.com's offering.

Exosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine, and regenerative medicine. In particular, cancer-derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.

The cargo contained within exosomes can offer prognostic information for a range of diseases - including cardiovascular, renal, neurodegenerative, and metabolic diseases - as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.

Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears, and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient's response to a specific course of treatment.

Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient's exosomes can be isolated, modified with the appropriate siRNA or protein, and injected back into the patient for treatment. Numerous approaches are being researched for creating drug-loaded exosomes and exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.

Story continues

The Era of Exosomes

For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to credit exosomes for a range of promising traits.

To date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. Within the past 5 years, there have been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.

Today the exosome industry is witnessing:

A surging number of scientific papers investigating exosomes and their applications

Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics

Swelling appetite among investors for exosome technology

An increasingly competitive IP environment

A diverse range of co-development partnerships

Proliferating numbers of exosome competitors in all major life science markets worldwide

This global strategic report about the exosome industry reveals:

The clinical pipeline for exosome therapeutics

Clinical trial activity by type, region, phase, and sponsor

Exosome industry events, including M&A activity, financing events, and IPOs

Strategic partnerships and co-development agreements

Competitors composing the global marketplace, including core technologies and products under development

Market size determinations by market segment, with forecasts through 2030

Exosome industry trends, competitive opportunities, and future directions.

Key Topics Covered:

1. REPORT OVERVIEW

2. EXOSOMES: AN OVERVIEW

3. EXOSOME ENGINEERING: THE NEW PLATFORM

4. MSC-DERIVED EXOSOMES IN REGENERATIVE MEDICINE

5. EXOSOME RESEARCH

6. COMMERCIALLY AVAILABLE EXOSOME RESEARCH TOOLS

7. SCIENTIFIC PUBLICATIONS IN EXOSOMES

8. EXOSOME PATENT LANDSCAPE

9. EXOSOMES: CLINICAL TRIAL LANDSCAPE

10. CURRENT STATUS OF EXOSOME MANUFACTURING

11. EXOSOME ISOLATION APPROACHES

12. DIAGNOSTIC APPLICATIONS OF EXOSOMES

13. THERAPEUTC APPLICATIONS OF EXOSOMES

14. APPLICATION OF EXOSOMES IN VACCINE DEVELOPMENT

15. CURRENT STATUS OF EXOSOME INDUSTRY

16. EXOSOME MARKET ANALYSIS

17. PROFILES OF EXOSOME MARKET COMPETITORS Companies Mentioned

101 Bio

AB

Abbexa, Ltd.

Abnova

Acquisition by Therillia

Adipomics, Inc.

Aegle Therapeutics

Aethlon Medical, Inc.

AgeX Therapeutics

Ambiotech

AmnioStem Stroke Therapy

AmniWrap

AMS Biotechnology, Ltd. (AMSBIO)

Anjarium Biosciences

Anjarium's Hybridosome Platform

Antibodies-Online GmbH

Aposcience AG

Aruna Bio

Avalon GloboCare Corp.

Avalon's Core Platforms

Aviva Systems Biology

AZ Platform

Azymus Therapeutics

Beckman Coulter Life Sciences

Bio-Techne

BioCat GmbH

BioDrone Technology

BioFluidica

Biological Dynamics, Inc.

Biorbyt, Ltd.

BioRegenerative Sciences, Inc.

BioVision, Inc.

BrainStorm Cell Therapeutics

BreStem Therapeutics, Inc.

Capricor Therapeutics

Carmine Therapeutics

CBD-Loaded Exosomes

CCT-

CD Bioparticles

Cell Care Therapeutics

Cell Factory BVBA/Esperite NV

Cell Guidance Systems, Ltd.

Cellarcus Biosciences, Inc.

Cevaris Plexaris

Ciola

CK-Exogene

Clara Biotech

Codiak Biosciences

Coya Therapeutics, Inc.

Craif, Inc.

Creative Bioarray

Creative Biolabs

Creative Medical Technology Holdings

Creative Proteomics

CreativeBiostructure

Curexsys GmbH

CUSABIO TECHNOLOGY LLC

Original post:
Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth - Yahoo...

19-year-old bobcat receives stem cell therapy for chronic arthritis – Channel3000.com – Channel3000.com – WISC-TV3

September 10, 2022 10:55 AM

Posted: September 10, 2022 10:55 AM

Updated: September 11, 2022 12:26 AM

Click here for updates on this story

SANDSTONE, Minnesota (WCCO) A 19-year-old bobcat has received stem cell therapy for chronic arthritis at The Wildcat Sanctuary in Sandstone, Minnesota.

On Thursday, the sanctuary announced that the bobcat, named Baby Jenga Blue, is believed to be the first bobcat in the world to receive this type of treatment. The procedure took place at the sanctuarys veterinary hospital.

This was thanks to Dr. Valerie Johnson, a veterinarian at Michigan State University, the sanctuary said in a release. Johnson grew the stem cells in a lab at MSU.

The stem cells were grown using fatty tissue from a healthy bobcat at the sanctuary.

Once the cells were ready for transplant, they were shipped to the sanctuarys veterinarian, Dr. Joanne Kamper. Then they were injected into Baby Jengas wrist joint and through IV infusion, which will help all joints through his blood stream, the release said.

It will take six weeks or longer to know the full effects of the treatment, but the sanctuary is optimistic the treatment will provide crucial relief for the big cat.

Please note: This content carries a strict local market embargo. If you share the same market as the contributor of this article, you may not use it on any platform.

Facebook

Linkedin

email

Print

View post:
19-year-old bobcat receives stem cell therapy for chronic arthritis - Channel3000.com - Channel3000.com - WISC-TV3

Girl, four, saves baby brother’s life by donating her stem cells on his 1st birthday – The Mirror

Exclusive:

Brave Aubrey Austin, four, donated her own stem cells and saved her baby brother Carey's life on the day he turned one, after he was diagnosed with a rare type of blood cancer aged just eight months

Image: Supplied via Lucy Laing)

A brave little girl saved the life of her baby brother on his first birthday.

Carey Austin was diagnosed with a rare type of blood cancer when he was just eight months old.

His only hope of survival was a stem-cell transplant.

Against all odds, his sister Aubrey, four, was a perfect match.

Surgeons operated on Careys first birthday and six months later he is cancer-free thanks to his big sister.

Image:

Their mum Naomi said: She absolutely adores Carey and when we explained to her about the transplant she wanted to do everything she could to save him.

Shes only four years old, yet she was only thinking of how she could help him. We felt so guilty putting her through an operation too, but it was Careys only chance of survival.

"She was so brave about it. She knew that her blood was going to save him.

During a two-hour procedure at Great Ormond Street Hospital, London, surgeons took out Aubreys stem cells and they were put into Careys body via a drip.

Naomi said: The fact that the transplant took place on Careys birthday was so significant that she was giving him a second chance at life on that special day.

The doctors and nurses said they had never seen anyone have a stem cell transplant on their birthday before.

Aubrey was very groggy and woozy when she came around from the operation, and she had puncture wounds on her back from where the stem cells had been taken out.

But she was still smiling through it all. She was so brave. She never complained about being in pain and she was just pleased to see how her little brother was afterwards.

Image:

Image:

When the brother and sister saw each other for the first time after the operation, there was not a dry eye in the room.

Naomi said: It was so sweet when they were reunited.

We took Aubrey to see Carey and she gave him a cuddle. They were thrilled to see each other again.

After a two-day hospital stay for Aubrey and seven weeks for Carey, the family were able to settle back into life back home in Brighton, East Sussex.

Carey is now in remission, with no signs of the cancer cells in his body.

But his parents have been warned that the disease is so aggressive that until March next year there is a 40% chance of it returning. After that, the likelihood falls to just 5%.

Naomi added: Two other children lost their lives on the cancer ward while we were there, so we know how lucky Carey has been.

He and Aubrey have always been close but now their bond is stronger than ever.

"Shes a superstar and he couldnt have wanted anything more from a big sister. Hes doing so well now. He loves playing with his cars and hes just learning to walk too.

Aubrey is with him all the time she just adores him. She knows that she has saved his life and she loves being a big sister to him. They play cars together and hes learning to walk, so she stands with him encouraging him to take his steps.

Image:

Carey fell ill last November but Naomi, a paediatric audiologist, and her husband Simon, a CPS lawyer, both 43, thought it was bronchitis because his sister had recently had the same thing.

A GP agreed but two days later he was rushed to hospital by ambulance with breathing difficulties.

Doctors at Great Ormond Street diagnosed juvenile myelomonocytic leukaemia, or JMML, which cannot be treated with chemotherapy. There are only 1.2 cases per million children in the UK each year.

Naomi said: I was hysterical. I kept trying to tell them that it wasnt cancer, it was bronchilitis. I couldnt accept what was happening.

Because parents are not suitable donors, Aubreys bone marrow was tested, a process that involves drawing a sample out using a needle.

Naomi said: There is only a 25% chance of any sibling being a match, so even with Aubrey we knew that the odds werent in our favour.

"If she hadnt been a match then we would have had to wait until doctors found an anonymous donor, but that may not have happened in time for Carey.

When the results came back to say that she was a perfect match for him, we couldnt believe it. We had been praying that she would save him, so to get the news that she was a match for him was just incredible.

When we heard I couldnt stop crying, it was so emotional. To think that Carey was going to have a chance of survival thanks to his big sister was the answer to our prayers.

The mum added: We did feel guilty about putting her through the procedure, but when we spoke to her about it, all she wanted to do was help. We were so proud of her.

The transplant was made even more special as it took place on March 15, which was Careys first birthday, giving the family a double celebration.

They are keen to raise awareness of the cancer symptoms and the charity Childhood Cancer and Leukaemia Group, which has helped them throughout their ordeal.

Naomi said: Having a child with cancer is one of the worst things that can happen to you. We didnt realise that it was leukaemia so we are thankful that it was spotted in time.

We received amazing support throughout from the hospital and from the CCLG.

We feel so lucky that Carey has come through it and it feels like a miracle to have him with us now.

Geoff Shenton, a childrens cancer specialist at Newcastle Upon Tyne Hospitals NHS Foundation, said: In a very small proportion of cases JMML can disappear on its own, but this is rare.

Most children will need a bone-marrow or stem-cell transplant. There is still a significant chance that the disease can relapse. There may be a possibility of a second transplant if this happens, but despite our best efforts, children still die from JMML.

For more information and support visit cclg.org.uk

Link:
Girl, four, saves baby brother's life by donating her stem cells on his 1st birthday - The Mirror

September is Blood Cancer Awareness Month: All You Need to Know – News18

September is observed as Blood Cancer Awareness month all over the world. During this month, activists and stakeholders work to raise awareness about the disease and the efforts being taken to fight blood cancers including leukemia, lymphoma, myeloma and Hodgkins disease.

The term blood cancer is a general description of various hematopoietic cancers. Our blood flows through blood vessels to supply all tissues in the body with nutrients. In the approximately 5 litres of blood circulating in our body there are billions of blood cells that carry out various vital functions. All blood cells originate from hematopoietic stem cells.

Haematopoietic stem cells are known as mother cells and do not yet have a specific function. They are able to renew and differentiate into cells with a specific function, thus replacing cells that die. In bone marrow, blood stem cells divide and develop into progenitor cells. Through further division, the progenitor cells mature and transform into different types of blood cells and then enter the bloodstream, says Dr Nitin Agarwal, HOD, Donor Request Management, DKMS BMST Foundation India.

Blood cancer is an abnormal proliferation (abnormal growth) of cells in the bone marrow especially white blood cells (WBCs). Cancer cells flood the bloodstream and drive out healthy cells. As a result, the blood can no longer perform its basic tasks, such as transporting oxygen and protecting the body from infection.

Leukemia This cancer is found in the bone marrow and the bloodstream. It is caused by abnormal rapid production of WBCs and high number of abnormal WBCs which cannot fight against infection, and they impair the bone marrows ability to produce red blood cells and platelets, says Dr Jimmy Mirani, Consultant Onco Surgeon, Wockhardt Hospital, Mumbai Central.

Lymphoma A type of blood cancer which affects the lymphatic system, which removes the risk excess fluids from body and generates immune cells. Lymphocytes are blood cells which are used to fight against infections. These abnormal lymphocytes become lymphoma cells which multiply and get collected in the tissues, adds Dr Mirani.

There are two types of lymphoma, namely, Hodgkins lymphoma and non-Hodgkins lymphoma.

Non-Hodgkins lymphoma: It mainly impacts the B-cell or T-cell. This type of lymphoma occurs more commonly than Hodgkins lymphoma. Can vary clinically and diagnostically into slow-growing ones to very aggressive types, notes Dr. Amrita Chakrabarti, Consultant, Haemato-Oncology & Bone Marrow Transplant, Max Hospital, Shalimar Bagh.

Hodgkins lymphoma This type of lymphoma affects the B cells. Broadly divided into classical Hodgkins and nodular lymphocyte predominant types. Occurs in the adolescence or elderly age group.

MyelomaIt is the cancer of plasma cells; WBCs which produce disease and infection fighting anti-bodies. Myeloma cells prevent the functions and productions of these antibodies leaving a week immune system.

Multiple myeloma This starts in the bone marrow when plasma cells begin to grow uncontrollably. As the cells grow, they compromise the immune system and impair the production and function of white and red blood cells causing bone disease, organ damage and anemia among other conditions, adds Dr Agarwal.

In most cases of blood cancer, the patient feels tired and weak. This happens because the number of red blood cells in the blood starts decreasing due to which there is a lack of blood in the person. Someof the commonsymptoms of blood cancers are fever, severe fatigue, bleeding from gums or skin, back ache, or bone pains, says Dr Pravas Mishra, Head Haematology/ Medical Oncology and BMT, Amrita Hospital, Faridabad.

Patients with myeloma might first present to an orthopaedical with a fracture originating from trivial trauma or to a nephrologist with a kidney dysfunction.Pain in bones and joints can be a symptom of not only arthritis but also blood cancer. Blood cancer is a disease in the bone marrow that is found in large amounts around the bones and joints.

Patientsmight present with nodes in the neck or axilla or groin or swelling in any part of the body. However most often a patientwith blood cancermight present with just a low haemoglobin. It is strongly advised not to ignore any anaemia, warns Dr Mishra.

A person suffering from blood cancer is prone to repeated infections. When leukemia cells develop in the body, then complaints of infection can be seen in the patients mouth, throat, skin, lungs, etc.

People who have cancer tend to have an abnormally low weight. If the body weight is reduced without any obvious cause, then it can be seen as the primary symptom of cancer.

The abnormal formation of leukemia cells in the body prevents the bone marrow from forming healthy blood cells such as platelets. Due to its deficiency, more bleeding problems can be seen from the nose of the patient, during menstruation and gums.

Blood cancer is diagnosed with the help of a wide range of diagnostic methods along clinical evaluation, such as blood tests, bone marrow tests, cytogenetic/karyotyping and molecular analysis, flow cytometry.

Myth: Blood cancer cannot be treated?

Fact: Once a patient is diagnosed with blood cancer, the first concern that comes to ones mind Is blood cancer curable?

Blood cancer is one type of cancer that has a high curability rate especially due to the advancement in the medical field, availability of newer, improved chemotherapy regimens, targeted therapy, and improved infection control measures. Timely diagnosis, especially early diagnosis, increases the chances of cure from blood cancer. Some of the other factors that impact the cure of blood cancer include the age of the patient, physical condition, presence of other comorbidities, stage of the disease, subtype of cancer, molecular factors, whether low grade/high grade, acute or chronic, the body parts that are affected and whether the disease is new onset or has come back after a previous cure.

You must understand that the cure or recovery from cancer is unpredictable, adds Dr. Chakrabarti.

There are cases when the patient has recovered even in the later stages of blood cancer. On the other hand, there are recorded cases where the patient couldnt recover even in the initial stages of blood cancer. So, its important to have realistic expectations and focus on following a healthy lifestyle with the advised treatment and measures. Early diagnosis and treatment play an important role in attaining cure.

Myth: All blood cancer patients need a bone marrow transplant

Fact: No, majority of patients suffering from blood cancers are treated without bone marrow transplant. A combination of chemotherapy, targeted therapy and immunotherapy is the best line of treatment.

Myth: Blood cancer occurs only in children?

Fact: No, blood cancers can occur in all age groups. All have a higher incidence in young children whereas Myeloid Leukaemia (MLL) is more frequently seen in senior citizens.

India is reeling under pressure of many misconceptions that exist amongst people about blood stem cell donation, its process and even its after-effects.

Myth: Once you donate blood stem cells, you will lose them forever.

Fact: Only a fraction of total stem cells is extracted during the process. Also, all the cells are naturally replenished within a few weeks

Myth: Donating stem cells is a really invasive and painful process

Fact: Blood stem cells are collected through peripheral blood stem cell collection (PBSC) which is completely safe and a non-surgical procedure. The process is similar to blood platelet donation that takes approximately three to four hours to complete and the donor can leave the collection center the same day.

Myth: Blood donation and a blood stem cell donation are same

Fact: Unlike blood collection for transfusion, blood stem cells are collected only when there is a match between the donor and patients human leukocyte antigen (HLA) combination (tissue type). So, you could be potentially the only match and life saver for a person with blood cancer in need of a transplant, adds Dr Nitin Agarwal. Blood stem cell donors donate only blood stem cells and the process is similar to a platelet donation.

Myth: Pregnant women cant register

Fact: This is untrue, a woman can register even during her pregnancy.

Myth: Stem cell donation leaves prolonged side-effects

Fact: No, there are no major side effects post blood stem cell donation. A person may only experience minor flu like symptoms because of the GCSF injections given to him/her before the donation, to mobilize blood stem cells in your blood stream.

Myth: Piercing and/or tattoo is a restricting factor

Fact: Piercing or a tattoo doesnt stop you from registering yourself to be a potential donor.

Myth: My blood stem cells can be stored

Fact: Your blood stem cells will not be stored. They last for around 72 hours and are delivered for the recipient straight to the hospital by a special courier. If the recipients body accepts them, the stem cells will start making healthy blood cells.

Myth: Joining a blood stem cell registry is no use. Most patients can find a stem cell donor within their own families

Fact: Per statistics, only 30% of blood disorder patients in need of a stem cell transplant are able to find a sibling match. About 70% of patients need an unrelated donor.

A registry like DKMS BMST Foundation India is a data bank of potential blood stem cell donors that houses details on thousands of committed blood stem cell donors. Any patient can benefit from this registry provided an HLA match.

Some of the blood cancer treatments include the following

Chemotherapy

This is the most important aspect of blood cancer treatment and involves using certain chemicals to kill the cancer-causing cells in the patients body. The prescribed drugs are given in a particular timeframe for the best possible improvement in the patients health. In some patients, a stem cell transplant is provided along with high dose chemotherapy.

Radiation therapy Radiation therapy helps to destroy cancer cells with the help of specific high-energy beams to kill cancer cells in precise areas of the body. This treatment is much beneficial for patients with lymphoma

Bone marrow transplant In this procedure, healthy stem cells are utilized to replace the cells affected by cancer. This helps the patients recover in the best possible manner. Can be autologous (where stem cells are taken from the patients own body) or allogenic (when a healthy donor gives stem cells to the patient.)

Targeted Therapy

Usually in the form of oral medications or pills. They are given alongside chemotherapy/ or radiotherapy and affect specific cancer cells and help in destroying them.

Read all the Latest Lifestyle News and Breaking News here

Continue reading here:
September is Blood Cancer Awareness Month: All You Need to Know - News18